Sofinnova Partners, one of Europe’s leading life sciences venture capital firms, has closed its latest flagship fund, Sofinnova Capital XI, at €650 million ($750 million)—substantially surpassing its initial target. The new fund strengthens the firm’s ability to invest in early-stage biopharmaceutical and medical technology companies developing solutions for significant unmet medical needs.
Sofinnova Capital XI will support a new wave of pioneering startups through the firm’s established multi-strategy platform. The fund will draw on the expertise of its experienced leadership team, including Partners Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter, and Graziano Seghezzi.
The fundraising attracted robust demand from a global pool of top-tier institutional investors. Backers include sovereign wealth funds, major pharmaceutical companies, corporates, insurers, foundations, and family offices. Investors from Europe, North America, Asia, and the Middle East participated, with strong re-up rates and notable new commitments—signaling continued confidence in Sofinnova’s disciplined, science-led investment approach.
Antoine Papiernik, Managing Partner and Chairman, described the close as a major milestone: “This fundraising marks a pivotal moment for Sofinnova. It gives us the firepower to double down on early-stage opportunities and reinforces our uniquely collaborative, science-driven investment approach. We’re excited to continue backing visionary entrepreneurs and advancing the next wave of breakthroughs in science and medicine to bring them to patients worldwide.”
Papiernik added that achieving such a result in today’s volatile fundraising environment underscores the strength of Sofinnova’s platform and the trust it has earned among investors.
Sofinnova Capital XI has already begun deploying capital into select portfolio companies. The fund will continue to invest in early-stage biotech and medtech ventures across Europe and North America, participating in both initial and follow-on financing rounds as it supports the next generation of scientific innovation.